- Doctors on Demand will integrate ResAppDx and SleepCheck into its online consultation offerings
- Agreement includes exchange of key data to support future reimbursement submissions
- Doctors on Demand are one of Australia’s largest private telehealth businesses
- Doctors on Demand provide both B2C and B2B offerings, with customers including Flight Centre, Allianz Partners and one of the world’s largest mining companies
Brisbane, Australia, 5 July 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, has signed a commercial agreement with Australian-based telehealth company Doctors on Demand. Doctors on Demand will launch ResApp’s smartphone-based acute respiratory diagnostic test ResAppDx in their video telehealth services in the third quarter of this calendar year.
Launched in 2015, Doctors on Demand offers both direct-to-consumer (B2C) and business-to-business (B2B) offerings for patients with a wide array of telehealth services including GP’s, psychiatrists and dietitians along with direct connection to 3,623 pharmacies for prescription fulfilment. Doctors on Demand’s B2B customers include Flight Centre, Allianz Partners and one of the world’s largest mining companies.
ResAppDx uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone’s built-in microphone. It is CE Marked in Europe and TGA approved for ARTG listing in Australia.
The deal also includes promotion of ResApp’s SleepCheck within Doctors on Demand’s virtual sleep clinic. SleepCheck is ResApp’s clinically accurate, hassle-free sleep apnoea screening test that provides a risk of sleep apnoea based upon breathing and snoring sounds during sleep.
Kirsty Garrett, CEO of Doctors on Demand said: “Doctors on Demand has built its growth through innovation and delivering the highest standards of medical care for the benefit of our B2C and B2B customers. We believe ResApp Health is offering world leading diagnostic support for the telehealth industry, which enables more patients to be effectively managed through this important setting. We’re very pleased to have reached this innovative agreement. Our team are very excited to implement this impressive technology to support the highest standards of care in clinical practice for our respiratory patients wherever they are in Australia, whether that’s at a remote mine site in the Pilbara or student accommodation in Sydney. We believe our collaboration with ResAppDx will support both organisations to continue to innovate in the delivery of remote care.”
CEO and Managing Director of ResApp, Dr Tony Keating said: “We are excited to have partnered with Doctors on Demand, one of Australia’s leading telehealth providers. This partnership will allow us to grow our volume within our home market and importantly will provide us with real world data to support our evidence base for future reimbursement submissions for ResAppDx. We look forward to working closely with Doctors on Demand to improve the remote management of respiratory disease in Australia.”
Doctors on Demand and ResApp Health have entered into an initial one-year partnership agreement (with the option of a mutually agreed additional year) for ResAppDx and SleepCheck to be implemented within the Doctors on Demands platforms for B2C and B2B customers. The agreement will see ResApp Health and Doctors on Demand collaborate to improve the patient experience and models of care for the remote management of respiratory disease (including sleep apnoea) and includes an exchange of deidentified patient data. The Agreement licenses the ResAppDx SDK to Doctors on Demand for their non-exclusive use in Australia. Doctors on Demand will also promote the SleepCheck app to its 125,000 patients as part of its virtual care offering. Either party may terminate the agreement by giving 90 days’ notice. At this point in time, ResApp Health does not expect this agreement to have a material impact on the company’s operating results.
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.